1: FEBS Lett 2003 Feb 27;537(1-3):17-22
Complement component anaphylatoxins upregulate chemokine expression by human
astrocytes.
Jauneau AC, Ischenko A, Chan P, Fontaine M.
Institut Federatif de Recherche Multidisciplinaire sur les Peptides No. 23,
INSERM U519, Faculte Mixte de Medecine et de Pharmacie, 22 Boulevard Gambetta,
76183 Cedex, Rouen, France
The complement (C) system, a major component of the innate immune system, has
been described as a factor implicated in some brain disorders. C activation
leads to the release of anaphylatoxins, two proinflammatory polypeptides acting
through specific receptors that have been detected on brain cells. Here, we
examined the effect of anaphylatoxins on chemokine expression by human
astrocytes. We showed that anaphylatoxins significantly increase chemokine mRNA
expression. However, anaphylatoxin-induced chemokine secretion (interleukin-8)
was observed only in the presence of interleukin-1beta. Thus, anaphylatoxins
could initiate a chemokine cascade and, at least in part, be involved in
pathogenesis of the brain.
PMID: 12606024 [PubMed - in process]
2: Clin Rheumatol 2003 Feb;22(1):56-61
Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O.
Rheumatology Department, Georges Pompidou Teaching Hospital, 20 rue Leblanc,
75015 Paris, France Tel.: 33 1 56 09 33 01 Fax: 33 1 42 29 33 16 E-mail:
debandt@club-internet.fr
Anti-TNF-alpha therapies are promising new strategies in the treatment of
rheumatoid arthritis (RA). Despite good clinical efficacy and tolerance, the
possible occurrence of drug-induced autoimmune disorders remains a matter of
concern. Induction of antinuclear (ANA) and anti-DNA antibodies is observed in
some patients treated with TNF-alpha inhibitors (anti- TNF-alpha antibodies) or
soluble TNF-alpha receptor. Of concern is the possibility of induction of true
lupus erythematosus by TNF blockers. Few cases without major organ involvement
were reported to be associated with infliximab treatment that resolved after
anti-TNF discontinuation. Only four cases have been described with the use of
etanercept. We report a new case of infliximab-induced lupus syndrome and two
new cases of etanercept-induced lupus syndrome in three patients with RA, all of
whom had previous isolated positive ANA.
PMID: 12605321 [PubMed - in process]
3: Ann Dermatol Venereol 2003 Jan;130(1 Pt 1):13
[Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone
(Lever scheme)]
[Article in French]
Benoit Corven C, Carvalho P, Prost C, Verret JL, Saiag P, Noblesse I, Bedane C,
Chosidow O, Young P, Roujeau JC, Joly P.
Service de Dermatologie, Hopital Charles Nicolle, INSERM U519, Rouen.
INTRODUCTION: The so-called "Lever scheme" therapeutic regimen has been proposed
in the borderline forms of pemphigus to reduce the side effects of systemic
corticosteroids.PATIENTS AND METHODS: A retrospective study was conducted in 8
hospital centers. The criteria for inclusion were the clinical diagnosis of
pemphigus, confirmed by histological examination and direct immunofluorescence
and first line therapy using the "Lever scheme" protocol, combining 40 mg of
prednisone on alternate days and 100 mg/day of azathioprine.RESULTS: Twenty-two
patients, seen between January 1990 and December 2000 were included in the
study. Eighteen patients (82 p. 100) exhibited complete healing of their
cutaneous-buccal lesions after a mean delay of 4.3 months. The lesions of 4
patients did not heal. Three of these patients died: a bed-ridden patient, a
patient exhibiting a metastatic bronchial carcinoma and a hypertensive patient
who died following a hemorrhagic cerebral vascular accident. Twelve patients (54
p. 100) were weaned off treatment after a mean duration of 2.9 years. Five
severe adverse events were observed: one pneumonia, 2 unbalanced diabetes, one
hepatitis and one pulmonary embolism.DISCUSSION: This study showed that the
healing of the cutaneous-buccal lesions was obtained using the "Lever scheme" in
18 cases out of 22 (82 p. 100). The delay to healing was relatively long in view
of the delayed effect of azathioprine. This limits the use of the "Lever scheme"
protocol to non-extensive and/or early stage pemphigus. The severe adverse
events occurred in low-weight patients in whom the dose related to weight was
the highest. Hence the doses of azathioprine and prednisone should be adapted to
patients' body weight.
PMID: 12605150 [PubMed - in process]
4: J Autoimmun 2003 Feb;20(1):91-5
Paraneoplastic pemphigus is associated with the DRB1*03 allele.
Martel P, Loiseau P, Joly P, Busson M, Lepage V, Mouquet H, Courville P, Flageul
B, Charron D, Musette P, Gilbert D, Tron F.
INSERM U519 IFR 23, Rouen, France
Pemphigus is a group of autoimmune blistering diseases caused by autoantibodies
directed against keratinocyte adhesion molecules. Pemphigus vulgaris (PV) and
pemphigus foliaceus (PF), in which autoantibodies bind, respectively, to
desmoglein 3 and desmoglein 1, are strongly associated with HLA-class II DR4 and
DR14 alleles. In paraneoplastic pemphigus (PNP), a rare variant associated with
neoplasia, autoantibodies target proteins of the plakin family in addition to
desmogleins 1 and 3. The presence of anti-desmoglein antibodies in all types of
pemphigus raises the question of common molecular mechanisms of susceptibility,
particularly similar MHC-class II allele associations, in the different forms of
the disease. HLA-DRB1 typing was performed in 13 PNP patients and results were
compared to those obtained from 84 healthy controls, 37 PV and 31 PF patients.
Our data demonstrate a significant association of PNP with HLA-DRB1*03 allele
which was found in 61.5% of the patients, whereas DRB1*04 and DRB1*14 appear not
to be involved in PNP susceptibility. Therefore, the HLA-genetic background of
PNP differs from that of other types of pemphigus, which suggests that distinct
mechanism(s) initiate(s) the immunological response in this form of pemphigus.
PMID: 12604316 [PubMed - in process]
5: J Autoimmun 2003 Feb;20(1):51-61
Optimization of an animal model of experimental autoimmune encephalomyelitis
achieved with a multiple MOG(35-55)peptide in C57BL6/J strain of mice.
Costa O, Divoux D, Ischenko A, Tron F, Fontaine M.
INSERM U-519 and IFRMP 23, Faculte de Medecine et de Pharmacie, 22 Boulevard
Gambetta, F-76183 Cedex 1, Rouen, France
The severity of the experimental autoimmune encephalomyelitis (EAE) induced by
peptide myelin oligodendrocyte glycoprotein(35-55)(pMOG(35-55)) is thought to be
predominantly influenced by the major histocompatibility complex (MHC), so that
C57BL6/J mice, on H2(b) strain, were only mildly sick. However, it remains
unclear as to how non-MHC gene regions affect EAE. To determine whether the
immunization protocol could have an influence on clinical signs, C57BL6/J mice
were immunized with a multiple antigen peptide (MAP) containing eight
pMOG(35-55)branches synthesized directly onto a lysine core, myelin
oligodendrocyte glycoprotein (35-55)-multiple antigen peptide (MOG(35-55)-MAP),
in complete Freund's adjuvant (CFA). In most of the mice, clinical onset (marked
weakness) occurred approximately at day 15. All mice injected with
MOG(35-55)-MAP had more severe symptoms than those injected with pMOG(35-55),
which developed no leg paralysis. All MOG(35-55)-MAP-immunized mice developed
EAE symptoms, but 50% had primary-progressive EAE, while the other 50% had
relapsing-remitting disease. Leukocyte infiltrations, associated with increased
glial fibrillary acidic protein (GFAP) expression by reactive astrocytes, were
observed around the lateral ventricles and blood vessels in the brain.
Significant positive correlations were established between
anti-MOG(35-55)antibody levels and clinical scores or GFAP positivity in the
spinal cord. The heterogeneity of EAE progression, observed in these genetically
identical individuals, suggests that the environment rather than the genetics
plays a role. This observation is highly pertinent as it corresponds to what is
seen in clinical MS.
PMID: 12604312 [PubMed - in process]
6: J Neurochem 2003 Mar;84(5):919-29
Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and
alpha-melanocyte-stimulating hormone breakdown in the rat brain.
Bellemere G, Morain P, Vaudry H, Jegou S.
European Institute for Peptide Research (IFRMP23), Laboratory of Cellular and
Molecular Neuroendocrinology, INSERM U 413, CNRS, University of Rouen,
Mont-Saint-Aignan, France Institut de Recherches Internationales Servier,
Courbevoie, France.
In the present study, we have investigated the effects of a novel prolyl
endopeptidase (EC 3.4.21.26, PEP) inhibitor, compound S 17092, on substance P
(SP) and alpha-melanocyte-stimulating hormone (alpha-MSH) metabolism in the rat
brain. In vitro experiments revealed that S 17092 inhibits in a dose-dependent
manner PEP activity in rat cortical extracts (IC50 = 8.3 nm). In addition, S
17092 totally abolished the degradation of SP and alpha-MSH induced by bacterial
PEP. In vivo, a significant decrease in PEP activity was observed in the medulla
oblongata after a single oral administration of S 17092 at doses of 10 and 30
mg/kg (-78% and -82%, respectively) and after chronic oral treatment with S
17092 at doses of 10 and 30 mg/kg per day (-75% and -88%, respectively).
Concurrently, a single administration of S 17092 (30 mg/kg) caused a significant
increase in SP- and alpha-MSH-like immunoreactivity (LI) in the frontal cortex
(+41% and +122%, respectively) and hypothalamus (+84% and +49%, respectively).
In contrast, chronic treatment with S 17092 did not significantly modify SP- and
alpha-MSH-LI in the frontal cortex and hypothalamus. Collectively, the present
results show that S 17092 elevates SP and alpha-MSH concentrations in the rat
brain by inhibiting PEP activity. These data suggest that the effect of S 17092
on memory impairment can be accounted for, at least in part, by inhibition of
catabolism of promnesic neuropeptides such as SP and alpha-MSH.
PMID: 12603817 [PubMed - in process]
7: Cephalalgia 2003 Mar;23(2):157-60
Hemicrania with response to indomethacin and prevalent autonomic symptoms: four
cases.
Donnet A, Lucas C, Massardier E, Boulliat J.
Neurosurgery, University Hospital Timone, Marseille, Neurology, University
Hospital, Lille, Neurology, University Hospital, Rouen, and Neurology,
Bourg-en-Bresse, France.
PMID: 12603375 [PubMed - in process]
8: Clin Chem 2003 Mar;49(3):505-7
Release of macromolecular cardiac troponin I complex after successful
percutaneous transluminal coronary angioplasty in acute myocardial infarction.
Lavoinne A, Cauliez B, Eltchaninoff H, Tron C, Cribier A.
Laboratoire de Biochimie Medicale and. Service de Cardiologie, Hopital Charles
Nicolle, Centre Hospitalier Univisitaire et Regional de Rouen, 76031 Rouen
cedex, France.
PMID: 12600968 [PubMed - in process]
9: Rev Mal Respir 2002 Oct;19(5 Pt 2):S21-5
[Article in French]
Cuvelier A.
Service de Pneumologie et Soins Intensifs, Hopital de Bois-Guillaume, CHU de
Rouen, 76031 Rouen.
PMID: 12599627 [PubMed - in process]
10: Neurochirurgie 2002 Dec;48(6):489-99
Angiographic cerebral vasospasm and delayed ischemic deficit on anterior part of
the circle of Willis. Usefulness of transcranial Doppler.
Proust F, Debono B, Gerardin E, Hannequin D, Derrey S, Langlois O, Weber J,
Freger P.
Service de Neurochirurgie, Hopital Charles-Nicolle, CHU Rouen, boulevard
Gambetta, 76031 Rouen Cedex.
BACKGROUND AND PURPOSE: After subarachnoid hemorrhage (SAH), cerebral vasospasm
(VS) may be revealed by cerebral angiography, during follow-up clinical
examination with the occurrence of delayed ischemic deficit (DID). Moreover,
transcranial Doppler (TCD) could be useful in determining the level of the
velocimetric threshold. The aims of the study were, on a prospectively collected
series of 460 patients, to assess angiographic VS incidence, to determine
possible risk factors, and to evaluate diagnostic sensitivity and specificity of
TCD.PATIENTS AND METHOD: A total of 460 patients consecutively operated on for
an aneurysm located on the anterior portion of the circle of Willis (mean age
47.2 +/- 14 years, sex ratio F/M=1.18) were included in the study. Preventive
treatment against VS was administered in all patients. On the 10(th) day, we
performed the following routine examinations: cerebral angiography, CT scan and
TCD.RESULTS: Angiographic VS occurred in 38.5% of the patients, and the single
risk factor was delayed admission (p=0.02, Mann-Whitney test). DID occurred in
15.6% and was complicated by cerebral infarct in 4.7%. The risk factors were
admission date (p=0.001, Mann-Whitney test) and severity of arterial narrowing
(significant tendency). Diagnostic sensitivity of TCD decreased from 83.6% for
MCA aneurysms, to 66.6% for ICA aneurysms and 40.6% for AcoA aneurysms.
Diagnosis specificity remained between 88.6% and 97.6% for the 3
locations.CONCLUSION: The unique risk factor for angiographic VS and DID was the
admission date. TCD demonstrated high specificity but its sensitivity was too
low for the aneurysms located far from the middle cerebral artery bifurcation.
PMID: 12595805 [PubMed - in process]
11: Gastroenterol Clin Biol 2003 Jan;27(1):125
[Extraluminal leiomyoma of the sigmoid colon and of the peritoneum]
[Article in French]
Costaglioli B, Descargues G, Songne B, Mace P, Scotte M.
Service de Chirurgie Generale et Digestive, Faculte de medecine, Pharmacie,
Centre Hospitalier Universitaire de Rouen, 1, rue de Germont, 76031 Rouen Cedex.
PMID: 12594379 [PubMed - in process]
12: Gastroenterol Clin Biol 2003 Jan;27(1):17-21
[Assessment of the quality and psychological impact of information delivered
using official consent forms in digestive endoscopy]
[Article in French]
Roque I, Hochain P, Merle V, Lerebours E, Hecketsweiler P, Ducrotte P.
Groupe de Recherche sur l'Appareil Digestif, Hopital Charles Nicolle, Rouen.
AIM: To test the impact of information brochures and informed consent forms in
patients undergoing digestive endoscopy procedures.METHOD: All patients
undergoing digestive endoscopy procedures during a two-month period were given
information about the procedure to be performed by delivery of an information
form produced by the French Endoscopy and Gastroenterology Societies. The
patients were then asked to sign an inform consent form. A questionnaire about
the informed consent form and the consent experience was given to all patients
after the endoscopic procedure.RESULTS: The questionnaire was completed by 108
consecutive patients. The informed consent form was completely read by 96.3% and
understood by 95%. Sixteen percent asked for complementary information, all
about complications. Twenty percent were distressed by the explanations.
Receiving written information was surprising for 22.2% of the patients, and
distressing for 18.5% mainly when endoscopy was planned without general
anesthesia (P=0.01 versus general anesthesia). Obtaining informed consent was
qualified as a normal procedure for 47.2%, but distressing for 19.4%. It was
considered by 41.1% as a way for doctors to be discharged from their
obligations.CONCLUSION: The informed consent forms written by scientific
societies are easy to understand. One third of the patients were distressed or
surprised to be given oral or written information. To sign a written consent
form before an endoscopy procedure is considered to be a means of discharging
practitioners from their responsibilities for 30% of the patients.
PMID: 12594361 [PubMed - in process]
13: J Gynecol Obstet Biol Reprod (Paris) 2002 Dec;31(8):741-6
[Ovarian pregnancies: revaluation of diagnostic criteria]
[Article in French]
Sergent F, Mauger-Tinlot F, Gravier A, Verspyck E, Marpeau L.
Clinique Gynecologique et Obstetricale, Pavillon Mere-Enfant, Hopital Charles
Nicolle, 1, rue de Germont, 76031 Rouen Cedex.
OBJECTIVES: To clarify the clinical features of ovarian pregnancy and to show
the incapacity of Spielberg's criteria to etablish the diagnosis. MATERIAL: and
method. Retrospective experience of ovarian pregnancies in a single maternity
unit over seven years with comparison between new diagnostic criteria and those
of Spiegelberg. RESULTS: Thirteen ovarian pregnancies identified (incidence=1
for 1400 deliveries). History of pelvic disease (one case), use of an IUCD (five
cases), pelvic pain (all the cases), metrorrhagia (four cases), hemorrhagic
shock (two cases). Diagnosis was evoked only once by ultrasound. Eleven patients
were treated by laparoscopy. None of the ovarian pregnancies in the present
series met the criteria of Spiegelberg's definition. CONCLUSION: Ovarian
pregnancy is a rare form of ectopic pregnancy, but its incidence is certainly
underestimated. Search for difficult to detect ultrasonographic features is
essential. Criteria, other than those described by Spiegelberg, when present
together confirm ovarian pregnancy: serum beta-hCG level 1000 IU / l and uterine
vacuity at vaginal ultrasonography; ovarian implication confirmed by surgical
exploration, with bleeding, visualisation of chorionic villi or presence of an
atypical cyst on the ovary; normal tubes; absence of serum beta-hCG after
treatment of the ovary. Ovarian pregnancy does not compromise subsequent
fertility of these patients. Recurrence is exceptional.
PMID: 12592193 [PubMed - in process]
14: J Gynecol Obstet Biol Reprod (Paris) 2003 Feb;32(1 Pt 2):77-8
[Reply to the letter from F. Sergent: vaginally inserted prostheses for the
treatment of prolapse]
[Article in French]
Sergent F, Marpeau L.
Clinique Gynecologique et Obstetricale, Pavillon Mere-Enfant, Hopital
Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen Cedex.
PMID: 12592189 [PubMed - in process]
15: J Pain Symptom Manage 2003 Feb;25(2):185-90
Hypocalcemia following pamidronate administration for bone metastases of solid
tumor. Three clinical case reports.
Champallou C, Basuyau JP, Veyret C, Chinet P, Debled M, Chevrier A, Grongnet MH,
Brunelle P.
Henri-Becquerel Center, Rouen, France
Bisphosphonates, such as pamidronate, are a new class of drugs, initially
described for treatment of neoplasic hypercalcemia. Currently, they also may be
used in the treatment of bone metastases from solid tumor, even without
hypercalcemia. Hypocalcemia is a potential adverse effect of these drugs, which
is considered infrequent and rarely symptomatic. We describe three cases of
severe hypocalcemia following one injection of pamidronate. The three patients
had bone metastases from solid tumors (breast in two cases, prostate in one), at
least partially osteoblastic, and none had hypercalcemia. The induced
hypocalcemia was rapid in onset, severe, and durable. The mechanism seems to be
multiple and may include both the expected reduction of osteolysis and also a
rapid and direct action on parathyroid glands followed by resistance to
parathormone. Some elements could amplify the phenomenon, such as latent
hypoparathyroidism after surgery, cervical radiotherapy, hypomagnesemia, or low
25 hydroxy vitamin D (25OH D). For patients who have such risk factors, it may
be useful to check calcium several days after the first injection.
PMID: 12590034 [PubMed - in process]
16: Skeletal Radiol 2003 Feb;32(2):78-81
Intermittent dislocation of the flexor hallucis longus tendon.
Renard M, Simonet J, Bencteux P, Raynaud P, Biga N, Thiebot J.
Department of Radiology, University Hospital-Charles Nicolle, 1 rue de Germont,
76031 Rouen cedex, France, Jacques.Thiebot@chu-rouen.fr
Dislocation of the flexor hallucis longus tendon is an exceptional occurrence.
To our knowledge, this is the first case ever reported of an intermittent
dislocation in a 17-year-old woman; she was a synchronised swimmer. She
consulted for a right internal retro-malleolar syndrome. Voluntary "snap" was
triggered by a mechanism which combined maximal ankle dorsiflexion and
interphalangeal plantar flexion of the toes. Non-enhanced dynamic helical CT and
axial MRI were performed, which revealed the dislocation of the right flexor
hallucis longus tendon outside the posterior intertubercular talar groove.
Static and dynamic imaging would appear to be required to make this uncommon
diagnosis.
PMID: 12589485 [PubMed - in process]
17: Am J Cardiol 2003 Feb 15;91(4):425-8
Effectiveness of percutaneous mechanical mitral commissurotomy using the
metallic commissurotome in patients with restenosis after balloon or previous
surgical commissurotomy.
Eltchaninoff H H, Tron C, Cribier A.
Department of Cardiology, Charles Nicolle Hospital, University of Rouen, Rouen,
France
Balloon mitral valvuloplasty has been reported to give equal or less positive
results after previous commissurotomy than after a first procedure. Percutaneous
mechanical mitral commissurotomy (PMMC) is a new technique that has not yet been
evaluated in this subset of patients. Of 1,175 PMMC procedures (1,175 patients),
173 patients (14.7%) had previous commissurotomy; patients were older (40 vs 35
years of age, p <0.0001) and more often in atrial fibrillation (34% vs 21%, p =
0.0016) than were patients who had not undergone previous commissurotomy. The
baseline transmitral gradient was lower (17 +/- 8 vs 19 +/- 8 mm Hg, p <0.002)
and the echocardiographic Wilkins score was higher (8.7 +/- 1.9 vs 7.6 +/- 1.8,
p <0.0001) for patients who underwent previous commissurotomy. Baseline mitral
valve area was comparable between the 2 groups (0.96 +/- 0.21 vs 0.93 +/- 0.24
cm(2)). Immediate results were satisfactory, although slightly less favorable
after previous commissurotomy, with a final mitral valve area of 2.01 +/- 0.30
versus 2.12 +/- 0.36 cm(2) (p <0.0001), and a residual transvalvular gradient of
5.0 +/- 3.6 versus 4.2 +/- 4.1 mm Hg (p = 0.003). The rates of procedural
success (93%) and severe complications (4.7%) were comparable between the 2
groups. Thus, PMMC is an effective and safe technique for the treatment of
mitral restenosis after previous commissurotomy.
PMID: 12586256 [PubMed - in process]
18: Endoscopy 2003 Mar;35(3):254
Sudden asphyxia due to a laryngeal lipoma following esophageal endosonography.
Lecleire S, Di Fiore F, Roque I, Antonietti M, Herve S, Savoye G, Michel P,
Lerebours E.
Digestive Tract Research Group, ADEN EA 3234, Rouen, France.
PMID: 12584652 [PubMed - in process]
19: Endoscopy 2003 Mar;35(3):223-5
Spontaneous passage of a dislocated esophageal metal stent: report of two cases.
Di Fiore F, Lecleire S, Antonietti M, Savoye G, Savoye-Collet C, Herve S, Roque
I, Hochain P, Ben Soussan E.
Digestive Disease Tract Research Group, Rouen University Hospital C. Nicolle,
Rouen, France.
Delayed transpyloric impaction is a very rare complication of esophageal
metallic stent placement. Authors report different endoscopic removal
techniques, but none of these has been validated yet because of their variable
success, time-consuming nature, and risk of perforation and hemorrhage. We
report that a "wait-and-see" approach is a safe and effective policy in patients
with permeable transpyloric impacted esophageal stents.
PMID: 12584641 [PubMed - in process]
20: Oncogene 2003 Feb 13;22(6):840-6
Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome
reveals a complete deletion of the TP53 gene.
Bougeard G, Brugieres L, Chompret A, Gesta P, Charbonnier F, Valent A, Martin C,
Raux G, Feunteun J, Bressac-de Paillerets B, Frebourg T.
Inserm EMI 9906-IFRMP, Faculty of Medicine, Rouen, France.
The absence of detectable germline TP53 mutations in a fraction of families with
Li-Fraumeni syndrome (LFS) has suggested the involvement of other genes, but
this hypothesis remains controversial. The density of Alu repeats within the
TP53 gene led us to search genomic rearrangements of TP53 in families without
detectable TP53 mutation. To this aim, we adapted the quantitative multiplex PCR
of short fluorescent fragments (QMPSF) method to the analysis of the 11 exons of
TP53. We analysed 98 families, either fulfilling (six families) or partially
meeting (92 families) the criteria for LFS, and in which classical methods had
failed to reveal TP53 alterations. We identified, in a large family fulfilling
the criteria for LFS, a complete heterozygous deletion of TP53. Additional QMPSF
analyses indicated that this deletion, which partially removed the centromeric
FLJ10385 locus, covered approximately 45 kb. This deletion was shown to result
from a complex rearrangement involving two distinct Alu-mediated recombinations.
We conclude that TP53 germline rearrangements occur as rare events, but must be
considered in LFS families without detectable point TP53 mutation.
PMID: 12584563 [PubMed - indexed for MEDLINE]
21: J Am Acad Dermatol 2003 Feb;48(2):279-81
Scleroderma-like cutaneous lesions induced by paclitaxel: A case study.
Kupfer I, Balguerie X, Courville P, Chinet P, Joly P.
Dermatology Department, the Pathology Laboratory, and the Oncology Unit, Rouen
University Hospital-Charles Nicolle.
Paclitaxel is a recent antineoplastic agent that belongs to the taxane family.
Its activity has been demonstrated in advanced and refractory ovarian, breast,
lung, and head and neck cancer. Adverse cutaneous reactions to paclitaxel have
been reported, namely bullous fixed drug eruption, onycholysis, acral erythema,
erythema multiforme, and pustular eruption. We report the first case of
scleroderma-like changes after paclitaxel administration. A 63-year-old patient
presented with an edematous and infiltrated erythema of the head, neck, axillae,
and left hand 10 days after administration of paclitaxel and paraplatin for
primitive peritoneal cancer. Cutaneous lesions improved after a change from
paclitaxel to cyclophosphamide. Cutaneous lesions recurred 3 months later, after
reintroduction of paclitaxel, and progressively evolved to cutaneous sclerosis.
Skin biopsy showed a dermal fibrosis. Biologic tests revealed no autoimmunity.
Scleroderma-like lesions of this patient were reminiscent of previously reported
cases that occurred after administration of docetaxel, which also belongs to the
taxan family. Thus, scleroderma-like syndromes seem to represent a unique
cutaneous adverse event caused by taxanes.
PMID: 12582404 [PubMed - in process]
22: Crit Care Med 2003 Feb;31(2):552-9
Noninvasive mechanical ventilation in clinical practice: A 2-year experience in
a medical intensive care unit.
Girault C, Briel A, Hellot MF, Tamion F, Woinet D, Leroy J, Bonmarchand G.
OBJECTIVE To evaluate the feasibility and outcome results of noninvasive
mechanical ventilation (NIV) in daily clinical practice outside any prospective
protocol-driven trial.DESIGN An observational retrospective cohort study.SETTING
A 22-bed medical intensive care unit in a university hospital.PATIENTS A
consecutive cohort of 124 patients who underwent 143 NIV trials, regardless of
the indication, over two consecutive years (1997-1998).INTERVENTIONS
None.RESULTS A total of 604 acute respiratory failure patients underwent
mechanical ventilation, and 143 NIVs were performed in 124 patients. The overall
prevalence of NIV use was 143 of 604 patients (24%) in three groups: hypoxemic
acute respiratory failure (29.5%), hypercapnic acute respiratory failure (41%),
and weaning/postextubation (29.5%). Intubation was avoided in 92 of 143 of the
NIVs performed (64%), 19 (13%) after changing the initial NIV mode (i.e., a
success rate of 62%, 51%, and 86% in the three groups, respectively). A total of
35 of 51 intubated patients (69%) required intubation during the first 24 hrs of
NIV. Intensive care unit stay was 12 +/- 10 days for the overall population, and
mortality, when NIV failed, was 13 of 124 patients (10.5%). Arterial pH (
=.0527) and the Pao /Fio ratio ( =.0482) after 1 hr were the only independent
predictive factors for NIV failure by multivariate analysis.(2) (2)CONCLUSIONS
This study confirms the results of controlled trials and demonstrates the
feasibility and efficacy of NIV applied in daily clinical practice. These
results suggest that NIV should be considered as a first-line ventilatory
treatment in various etiologies of acute respiratory failure and as a promising
weaning technique and postextubation ventilatory support. However, NIV should
certainly be performed by a motivated and sufficiently trained care team.
PMID: 12576965 [PubMed - in process]
23: J Urol 2003 Mar;169(3):921-4
Comment in:
J Urol. 2003 Mar;169(3):936-7.
Immunocyt test improves the diagnostic accuracy of urinary cytology: results of
a French multicenter study.
Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O,
Beurton D, Coulange C, Rambeaud JJ.
Urology Department, Charles Nicolle University Hospital, Rouen, France.
PURPOSE: The limitations of urinary cytology and the invasiveness of cystoscopy
generate an increasing interest in noninvasive diagnostic tools for the
management of transitional cell carcinoma. We assess the clinical performance of
ImmunoCyt (DiagnoCure, Inc., Saint-Foy, Canada) in the detection of bladder
cancer in a 10-center French trial. MATERIALS AND METHODS: From October 2000 to
April 2001, 694 patients undergoing cystoscopy were prospectively included in
the study. Of the patients 458 (66%) had been previously treated for superficial
transitional cell carcinoma and 236 (34%) were referred for symptoms suggestive
of bladder cancer. All patients underwent ImmunoCyt test and standard urinary
cytology from voided urine as well as a complete evaluation including cystoscopy
and transurethral resection or biopsy of suspicious lesions. Sensitivity and
specificity values of urinary cytology and ImmunoCyt whether or not combined
were calculated using cystoscopy as the gold standard and histopathology when
available. RESULTS: A total of 85 recurrent and 58 newly diagnosed bladder
tumors were diagnosed by cystoscopy and histologicaly confirmed. Overall
sensitivity of urinary cytology was 17.9%, 46.3% and 63.8% respectively, for G1,
G2 and G3 transitional cell carcinoma, whereas that of ImmunoCyt was 60.7%,
75.6% and 76.8%. Sensitivity of the combined tests was 66.7%, 78% and 87%,
respectively. Moreover, 10 of 55 (18.2%) new pT1 and pT2 or greater tumors were
diagnosed by ImmunoCyt alone. Specificity of urinary cytology was 94.5%, whereas
that of ImmunoCyt was 84.2%. Specificity of the combined tests was 80.7%. Marked
variations in urinary cytology sensitivity were observed among the different
centers (27.3% to 66.7%), whereas combined assays (urinary cytology and
ImmunoCyt) enhanced the overall sensitivity in the 80% range at most centers.
CONCLUSIONS: This prospective multicenter series confirmed a marked increase in
sensitivity without significant loss in specificity when including ImmunoCyt in
standard urinary cytology protocol. This increased sensitivity was observed in
high grade lesions (with 100% sensitivity for carcinoma in situ) as well in low
grade, low stage tumors.
Publication Types:
Multicenter Study
PMID: 12576813 [PubMed - indexed for MEDLINE]
24: Eur Respir J 2003 Jan;21(1):135-43
Effectiveness of oral moxifloxacin in standard first-line therapy in
community-acquired pneumonia.
Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, Hoffken G.
Clinical Institute of Pneumology and Thoracic Surgery, UVIR/Dept of Pulmonology,
Hospital Clinic of Barcelona, Villarroel, Barcelona, Spain.
atorres@medicina.ub.es
Based on recent guidelines for the management of community-acquired pneumonia,
this study was designed to evaluate the effectiveness of a new fluoroquinolone
compared with standard antimicrobial regimens, in conditions relating as closely
as possible to the real world setting. In this study, 564 patients were
randomised to either oral moxifloxacin (400 mg o.d.) or to standard oral therapy
(amoxicillin 1 g t.i.d. or clarithromycin 500 mg b.i.d. alone or in combination)
for up to 14 days using a double-blind procedure. The choice between the three
standard regimens was made by the clinician prior to randomisation. Clinical
response, quality of life, symptoms, healthcare resources and safety were
assessed. In the per-protocol population, clinical success was reported for 201
of 215 (93.5%) and 217 of 231 (93.9%) in the moxifloxacin and standard groups,
respectively, at 7-10 days post-therapy. At 28-35 days follow-up, continued
clinical cure was observed in 183 of 192 (95.3%) moxifloxacin and 207 of 221
(93.7%) standard groups. Drug-related adverse events were reported in 55 of 274
(20%) moxifloxacin and 86 of 279 (31%) standard patients with diarrhoea >5%.
Oral moxifloxacin monotherapy was as effective as, and better tolerated than,
optimal antibiotic strategy represented either by mono- or combination therapy
(amoxicillin and/or clarithromycin) in community-acquired pneumonia management.
PMID: 12570122 [PubMed - in process]
25: Fundam Clin Pharmacol 2002 Aug;16(4):281-7
Alpha2-adrenoceptor ligands inhibit alpha1-adrenoceptor-mediated contraction of
isolated rat arteries.
Artigues-Varin C, Richard V, Varin R, Mulder P, Thuillez C.
Department of Pharmacology, INSERM EMI 9920, IFRMP no23, Rouen University
Medical School, Rouen, France.
The experiments in this study were designed to investigate the potential
relaxing effects of different compounds known as alpha2-imidazoline ligands
(either agonists or antagonists) in isolated rat arteries, and to test the role
of nitric oxide (NO) and prostaglandins, in addition to the influence of the
nature of the contracting agent in these responses. Segments of mesenteric
arteries were isolated and mounted in a small vessel myograph (JP Trading,
Aarhus, Denmark) for isometric tension recording, while segments of gracilis
muscle arteries were cannulated and studied in the pressurized state using an
arteriograph (Living Systems Instrumentation, Burlington, VT, USA). In
phenylephrine precontracted mesenteric arteries, the agonists clonidine, BHT920,
UK 14304, and rilmenidine, as well as the antagonists idazoxan, yohimbine and
rauwolscine, all induced marked relaxations. Similarly, clonidine and idazoxan,
both induced marked dilatations of phenylephrine preconstricted gracilis muscle
arteries. In both mesenteric and gracilis muscle arteries, the responses to
clonidine and idazoxan were not affected by the NO synthase inhibitor
(omega)-nitro-L-arginine (L-NA, 10(-5) M) or the cyclooxygenase inhibitor
diclofenac (10(-5) M). In mesenteric arteries, the responses to clonidine or
idazoxan were similar when the arteries were precontracted by different
alpha1-adrenoceptor agonists (phenylephrine, methoxamine or norepinephrine). In
contrast, in arteries precontracted by PGF2alpha or endothelin, clonidine
induced contractions while idazoxan induced very modest relaxations. Thus,
alpha2-adrenoceptor/imidazoline ligands (whether agonists and antagonists)
induce paradoxical relaxation of small mesenteric or gracilis muscle arteries of
rats, which are not affected by NO-synthase or cyclooxygenase inhibition, and
appear related to direct non specific interactions of the alpha2-imidazoline
ligands with alpha1-adrenergic receptors in vascular smooth muscle.
PMID: 12570016 [PubMed - in process]
26: J Natl Cancer Inst 2003 Feb 5;95(3):242-3; author reply 243-4
Comment on:
J Natl Cancer Inst. 1999 Apr 21;91(8):691-6.
Re: Sex-related differences in bronchial epithelial changes associated with
tobacco smoking.
Paris C, Benichou J, Thiberville L.
Publication Types:
Comment
Letter
PMID: 12569147 [PubMed - indexed for MEDLINE]
27: Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2000;18(2):94-6
A NMRI suckling mouse model for the evaluation of infectivity of Cryptosporidium
parvum oocysts.
Xunde LI, Brasseur P.
Laboratoire de Parasitologie, Hospital Charles Nicolle, CHU, 76031, Rouen,
France.
OBJECTIVE: To evaluate the infectivity of Cryptosporidium parvum oocysts in NMRI
suckling mouse. METHODS: Four-day-old SPF NMRI suckling mice were inoculated
with different amounts of oocysts by oral gavage. On day 7 after inoculation,
suckling mice were sacrificed, and a suspension was prepared by homogenizing the
intestinal tract from pylorus to anus. A mouse was considered infected when
oocysts were found in smears of the intestinal content suspension stained with
carbo lfuchsin solution. The infectivity of oocysts was evaluated as measured by
the percentage of infected mice in each group. RESULTS: Mice receiving 1,500 or
2,000 oocysts were all infected. The percentages of infected mice were 88, 74,
51 and 28 respectively after ingestion of 1,000, 500, 250 and 100 oocysts. The
percentage of infected mice was 9.5% after ingesting as few as 50 oocysts.
CONCLUSION: This model is convenient for evaluation of the infectivity of C.
parvum oocysts.
PMID: 12567724 [PubMed - in process]
28: J Antimicrob Chemother 2003 Feb;51(2):473-5
Persistent acute tubular toxicity after switch from conventional amphotericin B
to liposomal amphotericin B (Ambisome).
Gerbaud E, Tamion F, Girault C, Clabault K, Lepretre S, Leroy J, Bonmarchand G.
Medical Intensive Care Unit and Department of Haematology, Charles Nicolle
University Hospital, Rouen 76031, France.
PMID: 12562731 [PubMed - in process]
29: Exp Gerontol 2002 Dec;37(12):1401-12
Transgenic mice expressing the human C99 terminal fragment of betaAPP: effects
on spatial learning, exploration, anxiety, and motor coordination.
Lalonde R, Dumont M, Fukuchi K, Strazielle C.
Universite de Rouen, Faculte de Medecine et de Pharmacie, 22 blvd Gambetta,
INSERM EPI 9906, Batiment de Recherche, Salle 1D18, 76183, Rouen Cedex, France
The functional consequence of beta-amyloid precursor protein (betaAPP)
manipulation on behavior was assessed in Tg13592 mice, characterized by
transgene expression of the 99 amino acid C-terminal sequence of human betaAPP
in brain and skeletal muscle but with plaque formation only in muscle. By
comparison to the C57BL/6 background strain controlled for age and gender,
Tg13592 transgenic mice had fewer movements in an automated chamber and fewer
enclosed arm entries in the elevated plus-maze. This hypoactivity was probably
due to a loss in the motivation to explore novel environmental stimuli rather
than motor weakness or anxiety. In addition, the acquisition of place learning
in the Morris water maze task was impaired in Tg13592 mice. The transgenic mice
were not impaired in a probe trial or while swimming toward a visible platform.
These results are concordant with the hypothesis that transgene expression of
the C-terminal sequence of human betaAPP in brain is sufficient for causing
behavioral abnormalities. The hypoactivity and the spatial learning deficit were
associated with higher cytochrome oxidase activity seen in thalamic nuclei,
indicating that altered regional brain metabolism caused by betaAPP transgene
expression may be responsible for the behavioral changes.
PMID: 12559409 [PubMed - in process]
